Fig. 1

MgH₂ treatment alleviates the progression of EAE. A Schematic diagram displaying the time course of EAE progression and interventions. B Average clinical score of EAE in mice of the control and MgH2-treated groups. n > 11 mice per group. C, D Representative spinal cord sections of H&E staining from EAE mice at 30 dpi and quantitative analysis of the number of infiltrating cells around lesion sites in WM of EAE mice (F = 2.6502). Infiltrating cells refer to the increased number of cells in the lesion area compared to the normal area. n = 3 mice per group. E–G Representative anti-Iba1 (red) and anti-GFAP (green) immunofluorescence of spinal cord sections around lesion sites of EAE mice at 30 dpi and quantitative analysis of Iba1⁺ cells/mm² (F = 0.2619) and GFAP⁺ cells/mm² (F = 3.5610), n = 3 mice per group. H–J Representative anti-CC1 (red) and anti-Sox10 (purple) immunofluorescence of spinal cord sections around lesion sites of EAE mice at 30 dpi and quantitative analysis of Sox10⁺ cells/mm² (F = 3.7464) and CC1⁺ cells/mm² (F = 1.8978), n = 3 mice per group. K, L Representative spinal cord sections of Luxol fast blue (LFB) staining of EAE mice at 30 dpi and quantitative analysis of the percentage of demyelinated WM in total WM (F = 1.0580). n = 3 mice per group. M, N Representative anti-MBP (green) immunofluorescence of spinal cord sections of EAE mice at 30 dpi and quantitative analysis of MBP⁺ area (F = 1.7836). n = 3 mice per group. Data are presented as mean ± SEM